We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals.
- Authors
Feihel, Dennis; Spier, Daniel; Stevens, Ty; Stefanov, Dimitre G.; Ahmadi, Ladan
- Abstract
In January 2021, cabotegravir/rilpivirine, the first extended-release injectable regimen for the treatment of Human Immunodeficiency Virus (HIV) was approved. Long-acting injections have the potential to improve adherence and viral suppression. We analyzed the acceptance rate of, and reasons for declining to switch to, the new regimen. During routine appointments, 102 people living with HIV (PLWH) were presented with information on the new medication and asked if they would like to switch from their current regimen. If they declined to switch, they were asked why. Sixty-nine percent of respondents declined to switch, with frequency of injections as the primary reason. Patients indicated they would be willing to switch if the interval between injections was longer. Forty percent of the patients accepting the injectable anti-retrovirals (ARVs) were not on any other medications. Barriers to switching to long-acting injectable ARVs include the need for more frequent provider visits, aversion to needles, and a perceived lack of evidence supporting the new medication.
- Subjects
HIV infections; ANTI-HIV agents; DRUG efficacy; INJECTIONS; ANTIRETROVIRAL agents; RILPIVIRINE; TREATMENT effectiveness; ACCEPTANCE &; commitment therapy; DRUGS; PATIENT compliance; PSYCHOLOGY of HIV-positive persons; PATIENT safety
- Publication
AIDS & Behavior, 2023, Vol 27, Issue 7, p2370
- ISSN
1090-7165
- Publication type
Article
- DOI
10.1007/s10461-022-03964-3